	A - !
human - CTA4. Is	
STATUS: This clone, which is cur.	entry
propring læge amounts of proprin in Ctto D444 methotner ata augisties.	is bain
Recently focus was brifter to the portion of this clone. Both Racapter and complement ac activities are determined by in CH2 domnia.	to toil Fe Livation
REFS: Confield + Morrison, 1981 June et al, 1991 J 1 TAD et el, 1991 J Orrean & Winter, 1988 M	rnunol. (147) Exp restingor
It would be useful to darin a c in which these Is tets vita Elininstro,	s vers
This work will be accept and what was done list year antibody alginearing project I delated the CHZ from & and mutates 235 and 237 in Jy	lageres to Jar to Jones N Pedide
See p 115, Book 1139 and // See p 52, Book 1177 and //	
Read and understood by me Date	

USE NESTRO PLR to goner. a mutatro SI from hct244 IJ. Clone the mSI back into hcorry. pNRDSH: Hand 111 pNROSH/hCTH4I1 light hctra4mt1 m preast cloré mutate residues as Illous: 237 Read and undgrstood by me

History Ecoli	
(5912) EURI] -> Smil site SHOULD Le JONE	-
(Blued by (5906) Small oralgement (5900) Rod II (5918) -> REMOVED less rediffered 5890) Rod II (5918) (1)	
(5260) Neo I - Eco RI (180)	
1 (840)	
pc Neo(R) OHFR - XA.I (1150) Control	
(Bam HI/Bal II) (1300)	
6190 bp (1370)	
Appr 1377 No. 1 (2373)	
By I (2373)	
TAMI TO THE TAME T	
(Bam HI 10 of II) (3250)	
preproinsulin poly A	
Engmes that Soo NOT CUT	
FLORY 1227 (3	
SpeI 1227 /3 KenI (1-1-12)	

Read and understood by me

Date



3	
٧.	(D)

5 primer A: une Gary Gray's original d', primer:

3' purher D	S' GATTECCE GAGETTANG	
75872 HCS:	S' GGATECCE GGGTACE GAGETTANG CLIAGGGG CCCATGG CTCGAGETTANG 3'	

PRIMER:

5' GCAGAGGAATTCGAGCT&GGTACCGGGGATCC.

	,
Read and understood by me	Date
11 111/	

B and C1	L L 4 4 P ercct4 444 44A CC4
B) s' conference Teagen Cot GA	GCF GAA 449 GCT GCC GAG 111 GCC GCA 111 GCA GCG GCG
GAAGGAGTCGTGGAC	1TCGGCTCCCCCGT ====================================
Tigonoclastide Repuents:	DNA SYNTHESIS REQUEST FORM
	REQUESTED BY Par Carrest
	PROJECT CHARGED 37 16T
A Company of the contract of t	DATE REQUIRED
	SEQUENCE: 5'GAGZATATCCCTGATCAGGA
	्रात्रवयस्यसम्बन्धन्त्र्विच्टाटानातः । विवयदास्तित्वसम्वयदानसम्बद्धानसम्यानसम्बद्धानसम्बद्धानसम्बद्धानसम्बद्धानसम्बद्धानसम्बद्धानसम्बद्धा
Read and understood by me	CCAACCC 3 2 3 3 3 3 3 5 3 5 3 5 5 5 5 5 5 5 5 5

////

male

men

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Gary S. Gray, Jerry Carson, Kashi Javaherian, Paul D. Rennert and Sandra Silver

Serial No.: 09/227,595 09/227,595

Filed: January 8, 1999 December 20, 2007

For: CTLA4-Cy4 Fusion Proteins (as amended)

Attorney Docket No.: RPN-001

Group Art Unit: 1642

Examiner: Helms, L.

Assistant Commissioner for Patents Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1-8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first elles mail in an envelope addressed to: Assistant Commissioner for Patents,

Washington, D.C. 20231 on the date set forth below.

Date of Signature and of Mail Deposit

By:

Megan E Williams Registration No. 43,270

Attorney for Applicants

Label No. EL 833315914US

DECLARATION UNDER 37 C.F.R. 1.131 BY

GARY S. GRAY, JERRY CARSON, KASHI JAVAHERIAN, PAUL D. RENNERT AND SANDRA SILVER

Sir:

We, Gary S. Gray, Jerry Carson, Kashi Javaherian, Paul D. Rennert And Sandra Silver declare:

1. We are the inventors of the subject matter described and claimed in the above-referenced patent application.

CN of

Serial No.: 09/227,595 Wen

Prior to July 11, 1994, the invention described and claimed in the above-2. referenced application was completed in this country, as evidenced by the following:

-2-

A. Prior to July 11, 1994, we were in possession of a cloned CTLA4Ig molecule which was producing large amounts of active protein in CHO DG44 cells.

Page A-1 of Appendix A describes amino acid modifications to the Ig portion of the CTLA4Ig molecule. Deletion of the CH2 domain from $\gamma 1$ and mutations to amino acids 235 and 237 in y4 are described.

Page A-2 of Appendix A describes amplification of the mutated γ4 Hinge-CH₂-CH₃ region and the cloning of the mutated γ4 into pNRDSH/hCTLA4 to replace the existing y1 Hinge-CH₂-CH₃.

Page A-3 of Appendix A describes a second method which involves the use of nested PCR to generate a mutated $\gamma 1$ (having an L to A substitution at amino acid 234, an L to E substitution at amino acid 235, and a G to A change at amino acid 237) from hCTLA4Ig and the cloning of the mutated γ1 back into hCTLA4 pNRDSH.

Pages A-5 and A-6 show primers for use in making mutated forms of CTLA4Ig.

The notebook pages submitted as pages A-1 through A-7 of Appendix A demonstrate that we completed the claimed invention in this country prior to July 11, 1994.

B. In addition, as shown on page A-8 of Appendix A, prior to July 11, 1994, we demonstrated that mutated forms of CTLA4Ig effectively competed with biotinylated CTLA4-Ig for binding to B7.

In the experiment presented at the bottom of the page B7Ig was put onto plates. Biotinylated CTLA4Ig was added to the plates in a fixed amount. Test forms of CTLA4Ig were added in serial dilutions to test for their ability to compete for binding to B7 on the plate. In this type of assay as the amount of an effective competitor is increased, the amount of biotinylated CTLA4Ig that binds decreases. This leads to a decrease in the optical density readout. Unlabelled CTLA4Ig (left row) was used as a positive control.

The data show that samples #2, #3, and #4 (in rows 2, 4, and 5, respectively) effectively competed with unmodified CTLA4Ig for binding to B7. As indicated in the table in the middle of the page, sample 2 was oncoCTLA4-my4; sample 3 was IgLCTLA4-γ1; and sample 4 was IgLCTLA4-γ1.

These data demonstrate that the modified CTLA4Ig molecules were still able to bind to B7.

Each of the dates deleted from pages A-1 through A-8 of Appendix A are prior to July 11, 1994.

We have been warned that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 or the United States Code, and that such willful and false statements may jeopardize the validity of the subject application or any patent resulting therefrom, and declare that all statements made of our own knowledge are true and that all statements made on information and belief are believed to be true.

Date:	Signed:
Date: 12001	Gary S. Gray Signed: Ferry Carson
Date:	Signed:Kashi Javaherian
Date:	Signed:Paul D. Rennert
Date:	Signed:Sandra Silver

This clone, which is corrently lorge amounts of matie proprin Ctto D444 methother atr amplifies. Recently focus Shiftso to the to trail this 1 racapter complement_activation ans activities are dathronines:-by in Ctt2 domind. Carpield + Marison, 1981 Jesp medingly REFS: Juno et al 1991 J (mnuno). (147) TAR et e., 1991_ J Exp nexton)101 Direan & Winter, 1988 NATure (832) It would be useful to darin a confrict in which these Is net vitias were Eliminstro, This work will be axactly analogous to whit was done list / year 1/a to antibody anymeering project, who indested the lated the CHz domin I delated the from 8, and mutatro peride 0.235 and 234 in fy See p 115, Book 1139 and / See p 52, Book. 1/77 ans, Read and understood by me

"hetery IJ. Clone the my brek into horry. PNROSH: KON! Saci ECORI pNROSH/hCTH4I) cip 31. light harrymoti PNROSH CLONE mutate residues 236 237 Date Read and undorstood by me

14:02 115	£ - R1	
(5912) EURI] , Smil	site should be gone	
(Start Market Ma	7 REMOVED	
pc Neo(R) OHFR - poly A 6190 -bp	Sph I (840) Neo I (860) Xho I (1150) (3am H1/Gq I I) (1300) Por Sph I (1370) Nco I (1533) (1533)	
preproinsulin poly A		
5	Engras that BOO NOT CUT ELORY 1227 13 SpaI 1227 13 KpnI (1-1-12)	
nderstood by me	Date	-

Read and u

Rull Rlown

F		81	MP.
A 12 12 12 12 12 12 12 12 12 12 12 12 12	11	,	

<u>O</u> .	3	
	C	(D)

5 primer A: une Gary GRAYS original d', primar:

3' puter D	Sent Soul For Soul Ecoli Sent Soul For Soul Ecoli S' GAATCCCC GGGTACC GAGCTC GAATTC S' GGATCCCC GGGTACC GAGCTC GAATTC	
19872 MCS:	5 GATGER GAGTACE GAGTE GA ATTE	
	CLTAGGGG CCCATGG CTCGAG CTTAAG	

PRIMER:

S' GCAGAGGAATTCGAG CTGGGTACCCGGGGATCC:

Read and understood by me	Date

Insull Com

B and C,	L L 4 9 P erc ct4 494 491 (c4
B) s' conference Teagen Cet 4AM	GC GAG GCC GCG GAG GCC GCG GAG GCC GCG GCG GCG GCG
2 6	TTCGGCTCCCCCGT
TEG TEA GTETTECCO	444TTT 444 5' C
Répuerts:	DNA SYNTHESIS REQUEST FORM
	REQUESTED BY Par Connect
	PROJECT CHARGED 37
	DATE REQUESTED.
College State Comment	DATE REQUIRED(NO ASAP)
AN ACTIVITY OF THE PARTY OF THE	SEQUENCE NAME
<u> </u>	LENGTH 67
	SEQUENCE:
	5'GAGCATTTCCTGATCAGGA
	_ ' शिनादायम्भामानान्द्रशिनादादादादादादादादादादादादादादादादादादाद
	LACIONAL CALLACTOR AND LACE AN
Ress and understood by me	CK-M-dciClll 1 3'
Grade H Com	

////

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Gary S. Gray, Jerry Carson, Kashi Javaherian, Paul D. Rennert and Sandra Silver

Continuation of

Serial No.: 09/227,595

Filed: January 8, 1999 - Decarber 20, 2001

For: CTLA4-Cy4 Fusion Proteins (as amended)

Attorney Docket No.: RPN-001

Group Art Unit: 1642

Examiner: Helms, L.

1.10

Assistant Commissioner for Patents Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents,

Washington, D.C. 20231 on the date set forth below.

Date of Signature and of Mail Deposit

Mailin Cabel No. EL 833315914US

Registration No. 43,270

Attorney for Applicants

DECLARATION UNDER 37 C.F.R. 1.131 BY

GARY S. GRAY, JERRY CARSON, KASHI JAVAHERIAN, PAUL D. RENNERT AND SANDRA SILVER

Sir:

We, Gary S. Gray, Jerry Carson, Kashi Javaherian, Paul D. Rennert And Sandra Silver declare:

We are the inventors of the subject matter described and claimed in the 1. above-referenced patent application.

2. Prior to July 11, 1994, the invention described and claimed in the above-referenced application was completed in this country, as evidenced by the following:

-2-

A. Prior to July 11, 1994, we were in possession of a cloned CTLA4Ig molecule which was producing large amounts of active protein in CHO DG44 cells.

Page A-1 of Appendix A describes amino acid modifications to the Ig portion of the CTLA4Ig molecule. Deletion of the CH₂ domain from $\gamma 1$ and mutations to amino acids 235 and 237 in $\gamma 4$ are described.

Page A-2 of Appendix A describes amplification of the mutated $\gamma 4$ Hinge-CH₂-CH₃ region and the cloning of the mutated $\gamma 4$ into pNRDSH/hCTLA4 to replace the existing $\gamma 1$ Hinge-CH₂-CH₃.

Page A-3 of Appendix A describes a second method which involves the use of nested PCR to generate a mutated $\gamma 1$ (having an L to A substitution at amino acid 234, an L to E substitution at amino acid 235, and a G to A change at amino acid 237) from hCTLA4Ig and the cloning of the mutated $\gamma 1$ back into hCTLA4 pNRDSH.

Pages A-5 and A-6 show primers for use in making mutated forms of CTLA4Ig.

The notebook pages submitted as pages A-1 through A-7 of Appendix A demonstrate that we completed the claimed invention in this country prior to July 11, 1994.

B. In addition, as shown on page A-8 of Appendix A, prior to July 11, 1994, we demonstrated that mutated forms of CTLA4Ig effectively competed with biotinylated CTLA4-Ig for binding to B7.

In the experiment presented at the bottom of the page B7Ig was put onto plates. Biotinylated CTLA4Ig was added to the plates in a fixed amount. Test forms of CTLA4Ig were added in serial dilutions to test for their ability to compete for binding to B7 on the plate. In this type of assay as the amount of an effective competitor is increased, the amount of biotinylated CTLA4Ig that binds decreases. This leads to a decrease in the optical density readout. Unlabelled CTLA4Ig (left row) was used as a positive control.

The data show that samples #2, #3, and #4 (in rows 2, 4, and 5, respectively) effectively competed with unmodified CTLA4Ig for binding to B7. As indicated in the table in the middle of the page, sample 2 was oncoCTLA4-my4; sample 3 was IgLCTLA4-γ1; and sample 4 was IgLCTLA4-γ1.

These data demonstrate that the modified CTLA4Ig molecules were still able to bind to B7.

Each of the dates deleted from pages A-1 through A-8 of Appendix A are prior to July 11, 1994.

We have been warned that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 or the United States Code, and that such willful and false statements may jeopardize the validity of the subject application or any patent resulting therefrom, and declare that all statements made of our own knowledge are true and that all statements made on information and belief are believed to be true.

Date:		Signed:	
			Gary S. Gray
Date:		Signed:	Jerry Carson
Date:	10_3_0	Signed:	Kashi Javaherian
Date:		Signed:	Paul D. Rennert
Date:		Signed:	Sandra Silver

Thomas - CDA4. IS
STATUS: This clave, which is corrently
propring læge amounts of metre proprin in Ctto D444 is bein methotner atr augifies.
Recently focus los shifts to the to the top toil portion of this clone. Both Fe [racepted and complement activation activities are determined by squence in CH2 domnin.
LEFS: Confield + Morrison, 1991 Jergmeding 4 June et al 1991 J immunol. (147) TARD et 2, 1991 J Exp reixing 102 Orcan & Winter, 1988 NATure (832)
IT would be useful to daring a confrict in which these Is tetovities were aliminates.
This work will be Exactly analogous to what was done list year I/a to anti-body assimeering project, whe I dalated the CHz domish from 8, and mutaters peride 235 and 237 in Jy
See p 115, Book 1139 and // See p 52, Book 1177 and //
Read and understood by me Date

USE NESTED PER to gener. a mutatro SI from hetery I . Clone the mfI back into heary. PNROSH : pNROSH/hCTH4I) cip 31. The first than the first of light harrymoti -in NRDSH cloré mutate residues 235 236... 235-Date Read and understood by me

Vactor

affer the first than the first two two the first two the f

H Will But the Hill Hall

Hind III Enory	
2 6481 7	
(Sq12) EURI (Sq02) SmoI (Obraval by (Sq00) xboI only (min) (Sq00) KNIII Bcl I (Sq18) -> REMOVED	
(5260) CLE CON PM FILE (180)	
7 (840) Sph I (840) Neo I (860)	
pc Neo(R) OHFR - XhoI (1150) (130)	•)
6190 pp	
Ampr 2373) Byl II (2373)	
(Oam H1/031 II) (3250)	
preproinsulin poly A	
Enzmes that 300 NOT CUT FLORY 1227 13	
Spe I 1217 p 3 5 Kpn I (4.4.02)	

Read and understood by me

Should Roma

Date

Fr	81	M.
C 700	,	

<u>O</u> .	3	
	C	(D)

5 primer). A: une Gary Gray's origine d', primer:

PRIMER

PROBLA

S'GAG CAT TIT CUT: GAT CATA GAG CUL AMA TET TET CHE AMA MET

CHE ARA TET CCA CUG TET CCA GGT AMA C TO TO TET CHE AMA MET

TO BOOTH - Smal-Kpri- Scal-Euri-Cul-Eurs-Ogez
TT promoter

3' purher D): XMI Sam HI SMI KANI SANI SCORE GA KTTC 5' GAATCCCC GAGGTC GA KTTC STORY TO COLOR CTTANS	
79872 MCS:	S' GGATICEC GGGTACC GAGCTC GA ATTC CCTAGGGG CCCATGG CT CGAG CTTAAG	
	3, 22, 1,4444	

PRIMER:

5' GCAGAGGAATTCGAGCTEGGTACCGGGGATCE

•		
Read and understood by me	 Date	
M a C		
11 MIL 1		

B and C,	L L 4 4 P ercct4 444 44A CC4
B) S' CCATCTCCTCAGCA CCT GA	1 7
n -	TTCGGCTCCCCCGT
TEG TCA GTCTTCC GGCAGT CAGAAGGG	664TTTT 646 51 C
5	
Forvelestide Requests:	DNA SYNTHESIS REQUEST FORM
Jonvoleotide Requests:	REQUESTED BY The Connect
Jonnelestie Requests:	REQUESTED BY Town Convert
Jonneleotide Requests:	PROJECT CHARGED 37 10T DATE REQUESTED. DATE REQUIRED (NO ASAP) SEQUENCE NAME MUSAmma 4 - 5 1
Forveleotide Requests:	PROJECT CHARGED 37 16T DATE REQUESTED. DATE REQUIRED_ (NO ASAP) SEQUENCE NAME
Jonneleotide Requests:	PROJECT CHARGED 37 16T PROJECT CHARGED 37 16T DATE REQUESTED. DATE REQUIRED
Reacand understood by ite	PROJECT CHARGED 37 10T DATE REQUIRED

/ // /

of IgCherus (3) Ig /FF12 A-8. DATE: 293 Transients THE GREEN CAMORE ug/inL Dilutions JgG4 1:10 > 1:2 IGG 1 ILL (12) (12) 1 12.12 *nco CTL114-m74 2 14.88 Ig L CTLH4 - Y1 3 | 34.26 ISC CTLAY(5)-87 4 33.9 35.54 D Contido 2.25 mg/s 156 mg/sc 2 pg/m 125 ng/m and find Optical Density 0.078 0.066 0.063 0.128 0.170 0.063 0.083 0.075 0.096 0.090 0.076 0.153 0.192 0.318 effectively conjecte 0.287 0.412 0.450 0.342 0.157 0.144 0.122 0.260 0.288 0.282 0.381 0.158 0.149 0.368 0.384 0.504 0.279 still NIA Sine -> Samples tetrial nevally 1.2 - in sor UIL -) All sample wells contain 507 of 707/m/ CTCANTY Read and understood by me Date

mew

44

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Gary S. Gray, Jerry Carson, Kashi Javaherian, Paul D. Rennert and Sandra Silver

Continuation of Serial No.: 09/227,595

Filed: January 8, 1999 December 20, 200

For: CTLA4-Cy4 Fusion Proteins (as amended)

Attorney Docket No.: RPN-001

Group Art Unit: 1642

Examiner: Helms, L.

Assistant Commissioner for Patents Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Mail to Malacee is mail in an envelope addressed to: Assistant Commissioner for Patents,

Washington, D.C. 20231 on the date set forth below.

Date of Signature and of Mail Deposit

Mail: as label No. EL 833315914US

Attorney for Applicants- Me A

DECLARATION UNDER 37 C.F.R. 1.131 BY

GARY S. GRAY, JERRY CARSON, KASHI JAVAHERIAN, PAUL D. RENNERT AND SANDRA SILVER

Sir:

We, Gary S. Gray, Jerry Carson, Kashi Javaherian, Paul D. Rennert And Sandra Silver declare:

We are the inventors of the subject matter described and claimed in the 1. above-referenced patent application.

2. Prior to July 11, 1994, the invention described and claimed in the above-

referenced application was completed in this country, as evidenced by the following:

A. Prior to July 11, 1994, we were in possession of a cloned CTLA4Ig molecule which was producing large amounts of active protein in CHO DG44 cells.

Page A-1 of Appendix A describes amino acid modifications to the Ig portion of the CTLA4Ig molecule. Deletion of the CH₂ domain from $\gamma 1$ and mutations to amino acids 235 and 237 in $\gamma 4$ are described.

Page A-2 of Appendix A describes amplification of the mutated $\gamma 4$ Hinge-CH₂-CH₃ region and the cloning of the mutated $\gamma 4$ into pNRDSH/hCTLA4 to replace the existing $\gamma 1$ Hinge-CH₂-CH₃.

Page A-3 of Appendix A describes a second method which involves the use of nested PCR to generate a mutated $\gamma 1$ (having an L to A substitution at amino acid 234, an L to E substitution at amino acid 235, and a G to A change at amino acid 237) from hCTLA4Ig and the cloning of the mutated $\gamma 1$ back into hCTLA4 pNRDSH.

Pages A-5 and A-6 show primers for use in making mutated forms of CTLA4Ig.

The notebook pages submitted as pages A-1 through A-7 of Appendix A demonstrate that we completed the claimed invention in this country prior to July 11, 1994.

B. In addition, as shown on page A-8 of Appendix A, prior to July 11, 1994, we demonstrated that mutated forms of CTLA4Ig effectively competed with biotinylated CTLA4-Ig for binding to B7.

In the experiment presented at the bottom of the page B7Ig was put onto plates. Biotinylated CTLA4Ig was added to the plates in a fixed amount. Test forms of CTLA4Ig were added in serial dilutions to test for their ability to compete for binding to B7 on the plate. In this type of assay as the amount of an effective competitor is increased, the amount of biotinylated CTLA4Ig that binds decreases. This leads to a decrease in the optical density readout. Unlabelled CTLA4Ig (left row) was used as a positive control.

The data show that samples #2, #3, and #4 (in rows 2, 4, and 5, respectively) effectively competed with unmodified CTLA4Ig for binding to B7. As indicated in the table in the middle of the page, sample 2 was oncoCTLA4-my4; sample 3 was IgLCTLA4- γ 1; and sample 4 was IgLCTLA4- γ 1.

These data demonstrate that the modified CTLA4Ig molecules were still able to bind to B7.

Each of the dates deleted from pages A-1 through A-8 of Appendix A are prior to July 11, 1994.

We have been warned that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 or the United States Code, and that such willful and false statements may jeopardize the validity of the subject application or any patent resulting therefrom, and declare that all statements made of our own knowledge are true and that all statements made on information and belief are believed to be true.

Date:	Signed:	
	Gary S. Gray	
Date:	Signed: Jerry Carson	
Date:	Signed: Kashi Javaherian	
Date: 3 October 2001	Signed: Paul D. Rennert	>
Date:	Signed: Sandra Silver	

Sportes: This clave, which is correnter amounts of matie lorge proprin CHODG44 methotner atr auxifies. Recently focus Portrail Pracapter Onftro to the ty tail this complement activation ans activities are dathronines by in Ctt 2 domnia. Carfield + Morrison, 1991 Jergmedryly Juno et al, 1991. J (mnuno). (147) TARD et e , 1991. J Exp neximior Direan & Winter, 1988 NATure (832) It would be useful to daring a construct in which these Is tetovitias were Elimenstro, This work will be acceptly analogous to Whit was done list / year 1/a to Jon 8, and mutater periode 235 and 237 in /4 See p 115, Book 1139 and See p 52, Book. 1/77 ans/ Read and understood by me

A-3 USE NESTED PLR to gener. a mutatro SI from interesty. Clone the mfI back into horry. pNROSH: that 111 PNROSH/hCTW4I1 cip 31. The limit will the will will light harrymoti PNRDSH cloré mutate residues 235 236... 237 Read and undorstood by me Date

4

Vactor

14:02 11	8.21	Z.0.R1	
(believed by (590) ornhapping (590) Aug antiples (590)	KNI BCI (5918)	- REMOVED	
(5260) CLI h	Neo(R) DHFR - poly A	SphI (840) Neo I (860) Xho I (1150)	
Amp	6190 - bp	(Ban HI/OGI II) (1300) SERVE (1370) NC. I (1333) NC. I (2373) BGI II (2373)	
pre proinsu	(Sem HI logII) (3250)	Enzones that	
	<i>5</i>	ODO NOT LUI ELIRY 1227 13 Spal 1227 13 Kpal (1-1-12)	
Read and understood by me	21	Date	

For	10 / The
ACTION E	

<u>Q</u>	3	
	C	(D)

5 primer A: une Gary Gray's original d', primer:

PRIMER

P BORT A

5'GAG CAT TIT CUT: GAT CATE GAG CUL AMA TET TET CAC AMA MET

CAC ACA TET CUA CUS TET CUA GGT AMA C TO TET CAC AMA MET

TO BOOTH - Smal - Kpri - Scal - Euri - Cual - Eurs - Oger
TT promoter

3' puter D): Xmil Samil Smil Kgril Samil Ecoki 5' GGATCCCC GGGGTACC GA ATTC 10 ATTCC CTCCAC CTTAAG	
19872 MCS:	S' GGATCCCC GGGTACC GAGCTC GA ATTC CCTAGGGG CCCATGG CT CGAG CTTAAG	
)'	

PRIMER.

5' GCAGAGGAATTCGAGCTGGGGATCC.

Read and understood by me	Date

Read and understood by me

B and C1	L L 4 4 P 2TC CT4 444 44A CC4
B) s' conterettecte age A CCT GA	4 4 C F GAA 449 GCT GCE GAG 111 GCA GCG GCG GCG GCG
	TTCGGCTCCCCGT
ELG TCA GTC+TC CTCTTCCC 4GCAGT CAGAAGGA GONUCLEOT LE Repuest:	999TTTT 999 5' ©
	REQUESTED BY Par Connect
•	PROJECT CHARGED 37
A CONSTRUCTION OF THE PARTY OF	DATE REQUESTED. DATE REQUIRED_ (NO ASAP) SEQUENCE NAME
	SEQUENCE: 5'GAGICATTATICKTIGATICAGGA
	्र ज़ित्रवयम्भागम्य ज्ञान्य वैद्यासम्बद्धान्य निर्माणका
Tee' Continued by the second b	CEANG-CITTIST 3' -
Real and understood b, me	

/ // /

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Gary S. Gray, Jerry Carson, Kashi Javaherian, Paul D. Rennert and Sandra Silver

Serial No.: 09/227,595

Filed: January 8, 1999 December 20, 2001

For: CTLA4-Cy4 Fusion Proteins (as amended)

Attorney Docket No.: RPN-001

Group Art Unit: 1642

Examiner: Helms, L.

Assistant Commissioner for Patents Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents,

Box Paket Helian Washington, D.C. 20231 on the date set forth below.

Date of Signature and of Mail Deposit

Mailing Lobel No. EL 833315914 US

By Megan E. Willia

Registration No. 43,270

Attorney for Applicants

DECLARATION UNDER 37 C.F.R. 1.131 BY

GARY S. GRAY, JERRY CARSON, KASHI JAVAHERIAN, PAUL D. RENNERT AND SANDRA SILVER

Sir:

We, Gary S. Gray, Jerry Carson, Kashi Javaherian, Paul D. Rennert And Sandra Silver declare:

1. We are the inventors of the subject matter described and claimed in the above-referenced patent application.

2. Prior to July 11, 1994, the invention described and claimed in the above-referenced application was completed in this country, as evidenced by the following:

A. Prior to July 11, 1994, we were in possession of a cloned CTLA4Ig molecule which was producing large amounts of active protein in CHO DG44 cells.

Page A-1 of Appendix A describes amino acid modifications to the Ig portion of the CTLA4Ig molecule. Deletion of the CH₂ domain from $\gamma 1$ and mutations to amino acids 235 and 237 in $\gamma 4$ are described.

Page A-2 of Appendix A describes amplification of the mutated $\gamma 4$ Hinge-CH₂-CH₃ region and the cloning of the mutated $\gamma 4$ into pNRDSH/hCTLA4 to replace the existing $\gamma 1$ Hinge-CH₂-CH₃.

Page A-3 of Appendix A describes a second method which involves the use of nested PCR to generate a mutated $\gamma 1$ (having an L to A substitution at amino acid 234, an L to E substitution at amino acid 235, and a G to A change at amino acid 237) from hCTLA4Ig and the cloning of the mutated $\gamma 1$ back into hCTLA4 pNRDSH.

Pages A-5 and A-6 show primers for use in making mutated forms of CTLA4Ig.

The notebook pages submitted as pages A-1 through A-7 of Appendix A demonstrate that we completed the claimed invention in this country prior to July 11, 1994.

B. In addition, as shown on page A-8 of Appendix A, prior to July 11, 1994, we demonstrated that mutated forms of CTLA4Ig effectively competed with biotinylated CTLA4-Ig for binding to B7.

In the experiment presented at the bottom of the page B7Ig was put onto plates. Biotinylated CTLA4Ig was added to the plates in a fixed amount. Test forms of CTLA4Ig were added in serial dilutions to test for their ability to compete for binding to B7 on the plate. In this type of assay as the amount of an effective competitor is increased, the amount of biotinylated CTLA4Ig that binds decreases. This leads to a decrease in the optical density readout. Unlabelled CTLA4Ig (left row) was used as a positive control.

The data show that samples #2, #3, and #4 (in rows 2, 4, and 5, respectively) effectively competed with unmodified CTLA4Ig for binding to B7. As indicated in the table in the middle of the page, sample 2 was oncoCTLA4-mγ4; sample 3 was IgLCTLA4-γ1; and sample 4 was IgLCTLA4-γ1.

CN of Serial No.: 09/227,595 MW -3- Art Unit 1642

These data demonstrate that the modified CTLA4Ig molecules were still able to bind to B7.

Each of the dates deleted from pages A-1 through A-8 of Appendix A are prior to July 11, 1994.

We have been warned that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 or the United States Code, and that such willful and false statements may jeopardize the validity of the subject application or any patent resulting therefrom, and declare that all statements made of our own knowledge are true and that all statements made on information and belief are believed to be true.

Date:	Signed: Gary S. Gray
Date:	Signed: Jerry Carson
Date:	Signed: Kashi Javaherian
Date:	Signed:Paul D. Rennert
Date: October 16,2001	Signed: Janlen Jelen

Sandra Silver

human-CDAY: IS
STATUS: This clave, which is corrently
propring longe amounts of medie propring in Ctto D444 is being methotnex at amplifies.
methotnerater amplifier.
Recently focus has brifted to the to the to the fail portain of this clone. Both
pacapter and complement activation
in CH2 domrid.
Juno et al 1991 J Expredista
TAB et 2 , 1991_ J Exp ressissor Orcan + Winter 1988 NATURE (832)
It would be useful to darin a confruct in which these Is tetovities were Eliminstro,
This work will be acceptly analogous to
ant body an en project, whe
from 8, and mutater peside
235 ans 234 in Jy
See p 115, Book 1139 and
See p 52, Book. 1/37 ans/
Read and understood by me Date


USE NESTO PLR to gener. a hCt2+4 IJ. Clone the mf1 mutatro 81 from book into horry. PNROSH: 42 pNROSH/hcta41, 31. Harm with the same light harrymoti -in NRDSH cloré mutate 234 235 236.... 237 Read and undgrstood by me Date ALK.

A-3

140	to

TJ:

T



Read and understood by me

Should Il Com

French Control of the	$H \mathcal{C}$
O 3	V 1 ~
5 primer A: use Gary Gary's original de prima:	
S'GAG CAT TIT CUT. GAT CAG GAG CUL MAR TET TET GAC AM AET CAR ARA TET CLA CUS TET CLA GGT ATTS C - PJFC -	
- Poonty-Smal-Kprl-Scal-Eurl-Cal-Eurs-Bylz-	
- Tt prometer	
3' produce D: Xmil Banni Smil Kpri Smil Ecki STR72 MCS: SqATCCCC GGGGTACC GAGCTC GAGTTC CCTAGGGGCCATGGCTCGAGCTTAAG 3' CCTAGGGGCCATGGCTCGAGCTTAAG 3'	
→	

PRIMER.			
S' GCAGAGGAATTCGA	rg ст 6 997 АССС99	ggATCE:	
lock			
			5
Read and understood by me	*,	Date	

B and C,	L L 4 9 P 2TCCT4 444 44A CC4
B) S' CCATCTCTTCAGCA CCT GA	1 × 1
GAAGGAGTCGTGGAC GAAGGAGAAGGG GGCAGTCAGAAGGGG	1TCGGCTCCCCCGT
Ejonucleotide Rejuents:	
	PROJECT CHARGED 37
	DATE REQUESTED. DATE REQUIRED_ (NO ASAP) SEQUENCE NAME
	SEQUENCE: 5' दिनिद्धिन न तन्दि न विकास कि
Real and understood by se	СЕМИ ФСТ 1 1 1 1 3 1 1 3 1 1
•	

////

A-7

Transient Expression of Tycherun43) Tg /FFIR DATE: 293 Transients gg/mL Dilutions 1:10 -> 1:2 1gG 1 ILL (12) 81 1 2:12 *nes CTL114-m84 2 14.88 Ig L CTLAY - YI 3 34.26 - Isc cring(3)-71 4 33.9 35.54 2.25 mg/c 156 mg/sc D Contido 2 pg/m 125 ng/m T. Optical Density 0.066 0.128 0.083 0.096 0.090 0.076 0.192 0.318 0.287 0.412 0.138 0.096 0.450 0.342 0.157 0.144 0.122 0,260 0.288 0.282 0.381 7.8 0.149 0,158 0.285 0.368 0.384 0.504 0.279 0.369 0.462 0.425 0.408 still ruga line -> Samples tetral nevally 1:2 - in 505 UIL -) All comple wells contain 500 of 707/m1 CTCAN by Read and understood by me Date

United States Patent & Trademark Office

Office of Initial Patent Examination - Scanning Division



Application deficien	cies found duri	ng scanning:	
□ Page(s)	of		were not present
for scanning.		(Document title)	
□ Page(s)	of		were not present
for scanning.		(Document title)	

□ Scanned copy is best available.

Sequence Listing page number starts on pag 52.